New Insights from the Phase III MARIPOSA Trial on Amivantamab and Lazertinib Combination for NSCLC Patients The MARIPOSA trial reveals promising results for the combination therapy of Amivantamab and Lazertinib in Asian NSCLC patients, indicating improved survival rates compared to single-agent therapy.

New Insights from the Phase III MARIPOSA Trial on Amivantamab and Lazertinib Combination for NSCLC Patients #Japan #Tokyo #NSCLC #Lazertinib #Amivantamab

New Treatment for Head and Neck Cancer Shows Promising Response Rates Johnson & Johnson's new study reveals RYBREVANT FASPRO™ displays a 56% response rate in advanced head and neck cancer treatment, highlighting its potential benefits.

New Treatment for Head and Neck Cancer Shows Promising Response Rates #United_States #Immunotherapy #Raritan #Amivantamab #RYBREVANT_FASPRO

Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients Johnson & Johnson's subcutaneous amivantamab injection approval marks a significant milestone in treating EGFR mutation-positive NSCLC, with improved efficacy.

Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients #Japan #Tokyo #NSCLC #EGFR_Mutation #Amivantamab

El medicamento #Amivantamab (administrado con una simple inyección) demostró potencial para reducir o frenar el crecimiento tumoral. Un paso crucial en la lucha contra el #CCEC.

‘Smart jab’ shows promise in treating advanced head and neck cancer ‘Smart jab’ shows promise in treating advanced head and neck cancer

🚨 A new treatment is showing real promise for head & neck cancer.

#Amivantamab shrank or halted tumours in 76 per cent of patients in a new trial presented at @myesmo.bsky.social by ICR's Professor Kevin Harrington and The Royal Marsden.

#ESMO25 #CancerResearch

Subcutaneous Amivantamab Shows Promise for Head and Neck Cancer with 45% Response Rate Johnson & Johnson reports a 45% response rate for subcutaneous amivantamab in head and neck cancer, with significant durability in patient responses.

Subcutaneous Amivantamab Shows Promise for Head and Neck Cancer with 45% Response Rate #None #Head_and_Neck_Cancer #JNJ #Amivantamab

Actualmente, existen 3 opciones de tratamiento de primera línea para mutaciones EGFR:

- #Osimertinib
- #Osimertinib + #Quimioterapia
- #Amivantamab + #Lazertinib

Si quieres saber más sobre estos tratamientos, únete al evento con la Dra. Ana Velázquez Mañana, MD MSc FASCO (Velazquez Manana)

OrigAMI-1 Trial at ESMO GI 2025: Amivantamab in mCRC The OrigAMI-1 trial explored the efficacy of amivantamab monotherapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC).

ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #OrigAMI1 #Amivantamab #mCRC #GIOnc

Breaking New Ground: Lazertinib and Amivantamab Boost Survival in EGFR-Mutant NSCLC Patients A groundbreaking combination therapy of Lazertinib and Amivantamab demonstrates significant survival benefits for patients with EGFR-mutant non-small cell lung cancer in recent clinical trials.

Breaking New Ground: Lazertinib and Amivantamab Boost Survival in EGFR-Mutant NSCLC Patients #Japan #Tokyo #NSCLC #Lazertinib #Amivantamab

💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.

Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo

48% asian, 39% white.
9% discontinued due to side effects

@oncoalert.bsky.social

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #CancerAwareness #BispecificAntibody #Immunotherapy #Blinatumomab #Blincyto #Amivantamab #Rybrevant #Vocabulary

Kein Zusatznutzen: Janssen nimmt Krebsmedikament vom Markt Lesen Sie, warum Pharmafirma Janssen Amivantamab vom deutschen Markt zurückzieht. Wie wirksam das Medikament ist, darüber streiten sich die Fachleute.

Trotz Zulassung plötzlich vom Markt: Das #Krebsmedikament #Amivantamab sollte Hoffnung bringen – doch der G-BA erkannte keinen Zusatznutzen. Was hinter dem Rückzug steckt, warum sich Fachleute streiten und Patientïnnen leiden: @sigridmaerz.bsky.social #archiv #krebs

Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes Janssen drug combination extends life expectancy during trial

#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...

The MARIPOSA effect 🦋
‼️Awaited OS data for #Amivantamab + lazertinib vs osimertinib in 1L EGFRm advanced #lungcancer presented at #ELCC25

🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎉> 1 yr mOS advantage
🚫no crossover allowed, ⬆️intracranial activity
⬇️toxicity over time w prophylactic mgmt (skin)
#lcsm

CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients - PharmaTimes Positive opinion issued for marketing authorisation extension

#oncology #CHMP #SC #Rybrevant #amivantamab #EGFRmutatedNSCLC #EGFRmutatedNSCLCpatients #marketingauthorisationextension #subcutaneousformulation #nonsmallcelllungcancer #NSCLC #lungcancer #JanssenCilag #phase3PALOMA3study #SCamivantamab #MedicalOncology
pharmatimes.com/news/chmp-re...

COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-m...

How to reduce skin toxicity from #amivantamab #lazertinib in #NSCLC?
📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴

EC approves Rybrevant with Lazcluze for advanced lung cancer - PharmaTimes New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

#Rybrevant #amivantamab #Lazcluze #lazertinib #advancedlungcancer #lungcancer #EGFRmutatedNSCLC #JanssenCilagInternational #advancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #thoraciccancer #EGFRmutationpositiveNSCLC #precisionmedicine #MARIPOSAstudy
pharmatimes.com/news/europea...

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer

Update on U.S. regulatory review of subcutaneous amivantamab

This is disappointing. I thought we would have #amivantamab subq formulation for EGFR+ #lungcancer for Xmas, which could make drug delivery easier, but @FDAOncology says not yet.

Update on U.S. regulatory review of subcutaneous amivantamab #lcsm www.jnj.com/media-center...